FDA and Health Canada joint regulatory submission pilot

15 January 2023
The U.S. Food and Drug Administration (FDA) is partnering with Health Canada to launch the joint eSTAR pilot. Requests for participating in the pilot are now open.
The pilot will test the use of a single regulatory submission to both the FDA and Health Canada.
The submission will need to include the GMDN Term for the product and therefore will be useful for demonstrating how the GMDN supports international harmonisation using an accurate generic name for the device type. Requests for participating in the pilot are now open.
More information is available from the FDA and Health Canada.
Health Canada
US FDA
www.fda.gov/medical-devices/how-study-and-market-your-device/health-canada-and-fda-estar-pilot
Recent Posts
- Blog – Manufacturers: The ‘Closest Match’ Term Dilemma for Devices July 4, 2025
- GMDN FOCUS – June 2025 June 30, 2025
- Blog – Reflecting on The Evolution of the Global Medical Device Nomenclature (GMDN) June 27, 2025
- Blog – The Role of GMDN in Reducing Barriers to the Global Medical Device Trade June 4, 2025
- GMDN FOCUS – May 2025 May 30, 2025